Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23819624 | 0.82 | KMT2A (0.39) | KMT2AATMTDP1ALDH1A1THRB | |
| SCHEMBL23803527 | 0.75 | RIPK1 (0.34) | RIPK1 | |
| SCHEMBL23819865 | 0.75 | RIPK1 (0.55) | KMT2ATDP1ALDH1A1THRBLMNA | |
| SCHEMBL23803518 | 0.71 | — | — | |
| SCHEMBL23803548 | 0.70 | RIPK1 (0.31) | RIPK1 | |
| SCHEMBL28777485 | 0.64 | KMT2A (0.75) | KMT2AATMALDH1A1THRBLMNA | |
| SCHEMBL27991188 | 0.63 | ALDH1A1 (0.54) | KMT2ATDP1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL10487075 | 0.63 | ALDH1A1 (0.53) | KMT2AATMALDH1A1CYP1A2 | |
| SCHEMBL27693199 | 0.63 | ALDH1A1 (0.66) | KMT2AATMTDP1ALDH1A1THRB | |
| SCHEMBL6169489 | 0.63 | AGER (0.47) | ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | SIRONAX LTD (KY) | 2024-10-29 | — | — | US | disclosed |
| US-20210284598-A1 | RIP1 Inhibitors | SIRONAX LTD (KY) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284598-A1 | RIP1 Inhibitors | RIPK1, RIPK3, RIPK4 | KMT2A 3181/4885ATM 3398/4885TDP1 320/4885 |
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | RIPK1, RIPK3, RIPK4 | KMT2A 3406/4885ATM 3315/4885TDP1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.